| Dr Tilina N Hu, MD | |
|
350 W Thomas Rd, Phoenix, AZ 85013-4409 | |
| (602) 406-3430 | |
| (602) 406-4058 |
| Full Name | Dr Tilina N Hu |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 20 Years |
| Location | 350 W Thomas Rd, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013181924 | NPI | - | NPPES |
| 434660 | Medicaid | AZ | |
| P00812937 | Other | AZ | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 37242 (Arizona) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | 81067 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Joseph's Hospital And Medical Center | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sjhmc Physician Services | 4486646197 | 533 |
News Archive
Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.
As researchers strive to find safe therapeutics for COVID 19, a study suggests that preventing the movement of cholesterol may inhibit viral entry by up to 80%.
New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections.
The global coronavirus pandemic has spread to 187 countries and territories, infecting more than 4.17 million people. Most countries, especially those with a skyrocketing caseload, grapple with a lack of hospital beds and facilities to cater to every patient infected with the virus. Now, a team of researchers may have the solution to this problem – a smart health system to monitor patients who are in home isolation.
Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).
› Verified 4 days ago
| Entity Name | Sjhmc Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326098005 PECOS PAC ID: 4486646197 Enrollment ID: O20040401001189 |
News Archive
Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.
As researchers strive to find safe therapeutics for COVID 19, a study suggests that preventing the movement of cholesterol may inhibit viral entry by up to 80%.
New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections.
The global coronavirus pandemic has spread to 187 countries and territories, infecting more than 4.17 million people. Most countries, especially those with a skyrocketing caseload, grapple with a lack of hospital beds and facilities to cater to every patient infected with the virus. Now, a team of researchers may have the solution to this problem – a smart health system to monitor patients who are in home isolation.
Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).
› Verified 4 days ago
| Entity Name | St. Joseph's Hospital And Medical Center C/o Dignity Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255382412 PECOS PAC ID: 6709863178 Enrollment ID: O20040702000601 |
News Archive
Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.
As researchers strive to find safe therapeutics for COVID 19, a study suggests that preventing the movement of cholesterol may inhibit viral entry by up to 80%.
New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections.
The global coronavirus pandemic has spread to 187 countries and territories, infecting more than 4.17 million people. Most countries, especially those with a skyrocketing caseload, grapple with a lack of hospital beds and facilities to cater to every patient infected with the virus. Now, a team of researchers may have the solution to this problem – a smart health system to monitor patients who are in home isolation.
Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tilina N Hu, MD 3030 N Central Ave Ste 1001, Phoenix, AZ 85012-2716 Ph: (602) 406-4786 | Dr Tilina N Hu, MD 350 W Thomas Rd, Phoenix, AZ 85013-4409 Ph: (602) 406-3430 |
News Archive
Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.
As researchers strive to find safe therapeutics for COVID 19, a study suggests that preventing the movement of cholesterol may inhibit viral entry by up to 80%.
New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections.
The global coronavirus pandemic has spread to 187 countries and territories, infecting more than 4.17 million people. Most countries, especially those with a skyrocketing caseload, grapple with a lack of hospital beds and facilities to cater to every patient infected with the virus. Now, a team of researchers may have the solution to this problem – a smart health system to monitor patients who are in home isolation.
Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).
› Verified 4 days ago
Donald A Tobias, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 97 Biltmore Est, Phoenix, AZ 85016 Phone: 602-956-3209 | |
Nicole Warrington, MD Radiology Medicare: Medicare Enrolled Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 602-839-2266 | |
Daniel Fosu, Radiology Medicare: Not Enrolled in Medicare Practice Location: 16220 N 7th St Apt 2136, Phoenix, AZ 85022 Phone: 480-469-0283 | |
Sanford Ornstein, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 350 W Thomas Rd, Phoenix, AZ 85013 Phone: 602-406-3430 Fax: 602-406-4058 | |
Dr. Abhilash P Nambiar, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4611 E Shea Blvd Ste 120, Phoenix, AZ 85028 Phone: 602-441-3845 | |
Alicia Chen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 |